# A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp

> **NCT03123471** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 303 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Apremilast
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03123471
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-16
- **Primary completion:** 2018-08-13
- **Final completion:** 2019-01-09
- **Target enrollment:** 303 (ACTUAL)
- **Last updated:** 2020-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03123471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03123471, "A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03123471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*